23-MEL-13-VMT-PMC (VMT01-T101): A Phase I/IIa, First-In-Human, Multi-Center Dose Escalation and Dose Expansion Study of [203/212Pb]VMT01 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Patients With Previously Treated Unresectable or Metastatic

Grants and Contracts Details

StatusActive
Effective start/end date9/21/239/21/25

Funding

  • Viewpoint Molecular Targeting Incorporated: $29,007.00